AI assistant
Median Technologies — Capital/Financing Update 2016
Jul 6, 2016
1514_rns_2016-07-06_7ffc1390-3665-4a82-9453-715dcde78edc.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Press Release
Half-Year MEDIAN Technologies liquidity contract statement contracted with AUREL BGC Company
Sophia Antipolis, France – July 6 th 2016 – Under the liquidity contract entrusted by MEDIAN Technologies to AUREL BGC, the following resources were listed in the liquidity account as at June 30, 2016:
- € 72,165.89
- 18,833 shares
For information, as at December 31, 2015, the following resources were listed in the liquidity account:
- € 90,602.01
- 17,303 shares
About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care.
MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com
"We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients."
Contacts
MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 [email protected] Press ALIZE RP Caroline Carmagnol Wendy Rigal + 33 1 44 54 36 66 [email protected] Investors ACTIFIN Ghislaine Gasparetto + 33 1 56 88 11 11 [email protected]